According to a report by the media outlet Ismorbo on January 22, the U.S. Food and Drug Administration (FDA) recently revealed that cannabis is considered to have legitimate medical uses and has proposed reclassifying it from a Schedule I substance to a Schedule III substance. This decision has sparked widespread attention and discussion.
The FDA has stated that compared to other substances classified as Schedule I or II drugs, marijuana poses a lower threat to public health. While some individuals may face risks due to excessive use of marijuana, the majority of marijuana users do not pose significant risks to themselves or others.
When assessing the risks and benefits of marijuana, the FDA has chosen to use alcohol as a reference standard, despite alcohol not being classified as a controlled substance. The agency acknowledges that there is scientific evidence supporting the use of medical marijuana in treating various symptoms, including but not limited to appetite loss, anxiety disorders, epilepsy, inflammatory bowel diseases, nausea and vomiting, pain, and post-traumatic stress disorder. However, the FDA emphasizes that this does not mean that the safety and effectiveness of marijuana have been fully established.
This proposal could provide more operational freedom for cannabis companies and alleviate tax restrictions dating back 40 years. However, the decision does not explicitly endorse the use of marijuana for treating specific health conditions. This reclassification could also stimulate further research on cannabis, opening up new possibilities for the future development of this field. The long-term impact of this decision on the cannabis industry and related sectors is being closely watched.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
